الولايات المتحدة · منصات وبيانات · Finviz

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation ...

نشره Finviz · الولايات المتحدة منذ 14 س

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that results from its Phase 1b…

اقرأ المقال كاملًا على Finviz سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (finviz.com)

يستحق القراءة أيضًا

The Motley Fool

3 signs cash-strapped consumers are nearing a ‘spend-pocalypse’ that would hurt the economy

Investing.com

Taco Bell sales fall more than expected on cyclosporiasis outbreak hit

Benzinga

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation ...

مشاركة

يستحق القراءة أيضًا

Offerpad (OPAD) Q3 2026 Earnings Call Transcript

Delta blasts a Heathrow Airport operational decision

Axa Sa (OTCMKTS:AXAHY) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

3 signs cash-strapped consumers are nearing a ‘spend-pocalypse’ that would hurt the economy

Taco Bell sales fall more than expected on cyclosporiasis outbreak hit

Best Biotech Stocks Right Now